US 2016/0095903 A1 · EXTENDED RELEASE OF NEUREGULIN FOR IMPROVED CARDIAC FUNCTION

Abstract

The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.

Claims2

Dependent claims

A method for preventing, treating or delaying a disease or disorder in a mammal, the method comprising extended release of neuregulin into a mammal.

Dependencies are inferred from the claim text.

Facts

Application

14/965,790Filed 10 Dec 2015

Priority

30 Dec 2005

Published

7 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 38/1883
Growth factors; Growth regulators: neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 47/60
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes: the organic…
A61K 48/00
Medicinal preparations containing genetic material which is inserted into cells of the

Family

Application60/755,124Us provisional application · filed 30 Dec 2005

Application60/758,626Us provisional application · filed 13 Jan 2006

Application11/648,061Division · filed 29 Dec 2006

Application14/965,790Division

US 11,638,746 B2Related patent

US 2007/0190127 A1Published application

US 2016/0095903 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

14/965,790Filed 10 Dec 2015

Priority

30 Dec 2005

Published

7 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 38/1883
Growth factors; Growth regulators: neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 47/60
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes: the organic…
A61K 48/00
Medicinal preparations containing genetic material which is inserted into cells of the

Family

Application60/755,124Us provisional application · filed 30 Dec 2005

Application60/758,626Us provisional application · filed 13 Jan 2006

Application11/648,061Division · filed 29 Dec 2006

Application14/965,790Division

US 11,638,746 B2Related patent

US 2007/0190127 A1Published application

US 2016/0095903 A1This patent

From the US filing history. Foreign family members aren’t listed.

Extended release of neuregulin for improved cardiac function

Life of this patent

Abstract

Claims2

Extended release of neuregulin for improved cardiac function

Life of this patent

Abstract

Claims2